RxDoctor Payments Data

Erin McGuinn, MD

Cardiovascular Disease · Aurora, CONPI 1467895441

Payments from drug & device makers

$697in general payments, 2019–2025

Across 25 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$229
  • Edwards Lifesciences$121
  • E.r. Squibb & Sons, L.L.C.$95
  • Pfizer$46
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33
  • AbbVie$29
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$697100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$697 in reported general payments places this provider in the 35th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$96,203
Medicare patients
396
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$94,845
JardianceEmpagliflozin87$70,626
FarxigaDapagliflozin Propanediol31$26,397
EntrestoSacubitril/Valsartan37$24,871
Repatha SureclickEvolocumab27$14,822
OzempicSemaglutide12$10,774
Metoprolol Succinate184$2,519
Amiodarone Hcl23$1,438
Atorvastatin Calcium97$875
Ezetimibe29$826
Rosuvastatin Calcium71$769
Spironolactone83$481
Amlodipine Besylate42$469
Losartan Potassium48$464
ClopidogrelClopidogrel Bisulfate17$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$94,84576 claims
NovartisEntresto$20$24,87137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →